Catalent (CTLT) has been in the limelight recently, due to its
impending acquisition by Novo Holdings. This massive deal worth $16.5 billion has drawn attention not only from various investment and fund management entities but also from regulatory watchdogs. Consequently, EU antitrust regulators are expected to voice their stance on Novo’s Catalent buy by Dec 6. On the financial front, CTLT presented mixed results. It
missed Q1 revenue estimates but trumped Q4 earnings and revenue predictions. Despite the earnings miss, Catalent’s stock demonstrated resilience with its gross margin improving. As the company navigates through its deal with Novo Holdings, it managed to strike an agreement to
sell its Somerset, NJ Oral Solids Facility. Institutional stakeholders have been active;
Verition Fund Management LLC decreased its stake, whereas
Citigroup Inc., Bank of Montreal, Charles Schwab Investment Management, and ING Groep NV amplified their holdings. However, the acquisition is not without opposition. US Senator Warren has expressed scrutiny concerns, and consumer groups have requested FTC to block the deal. Amid these developments, CTLT has announced that its CEO will remain at the helm post-acquisition.
Catalent CTLT News Analytics from Mon, 05 Feb 2024 08:00:00 GMT to Sat, 30 Nov 2024 11:46:40 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -7
